tipifarnib has been researched along with posaconazole in 4 studies
| Studies (tipifarnib) | Trials (tipifarnib) | Recent Studies (post-2010) (tipifarnib) | Studies (posaconazole) | Trials (posaconazole) | Recent Studies (post-2010) (posaconazole) |
|---|---|---|---|---|---|
| 309 | 92 | 94 | 1,575 | 103 | 1,014 |
| Protein | Taxonomy | tipifarnib (IC50) | posaconazole (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 8.1 | |
| Steroid 17-alpha-hydroxylase/17,20 lyase | Homo sapiens (human) | 0.921 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.2458 | |
| Aromatase | Homo sapiens (human) | 8.4 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 7.2 | |
| Cytochrome P450 11B1, mitochondrial | Homo sapiens (human) | 0.31 | |
| Cytochrome P450 11B2, mitochondrial | Homo sapiens (human) | 0.021 | |
| Sterol 14-alpha demethylase | Trypanosoma cruzi strain CL Brener | 0.464 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buckner, FS; Gelb, MH; Karimi, M; Kraus, JM; Lepesheva, GI; Verlinde, CL | 1 |
| Arif, J; Buckner, FS; Chennamaneni, NK; Gelb, MH | 1 |
| Arif, J; Buckner, FS; Chennamaneni, NK; Gelb, MH; Karimi, M; Kraus, JM; McGuffin, SA; Tatipaka, HB; Verlinde, CL | 1 |
| Bahia, MT; Buckner, FS; Charman, SA; Chatelain, E; Chennamaneni, NK; Gelb, MH; Hulverson, MA; Laydbak, JU; Lepesheva, GI; Scandale, I; Shackleford, DM; Suryadevara, PK; Verlinde, CL; White, KL | 1 |
4 other study(ies) available for tipifarnib and posaconazole
| Article | Year |
|---|---|
Rational modification of a candidate cancer drug for use against Chagas disease.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Chagas Disease; Humans; Mice; Mice, Inbred BALB C; Models, Molecular; Quinolones; Rats; Trypanocidal Agents | 2009 |
Isoquinoline-based analogs of the cancer drug clinical candidate tipifarnib as anti-Trypanosoma cruzi agents.
Topics: Animals; Antineoplastic Agents; Chagas Disease; Drug Evaluation, Preclinical; Mice; Molecular Conformation; Parasitic Sensitivity Tests; Quinolones; Stereoisomerism; Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma cruzi | 2009 |
Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.
Topics: 3T3 Cells; Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Chagas Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Humans; Isoenzymes; Mice; Models, Molecular; Protein Binding; Quinolones; Rats; Sterol 14-Demethylase; Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma cruzi | 2010 |
Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib.
Topics: 14-alpha Demethylase Inhibitors; Administration, Oral; Alkyl and Aryl Transferases; Animals; Chagas Disease; Crystallography, X-Ray; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Female; Humans; Mice; Models, Molecular; Nitroimidazoles; Quinolones; Structure-Activity Relationship; Triazoles; Trypanocidal Agents; Trypanosoma cruzi | 2012 |